Health state utility values in schizophrenia: protocol for a systematic review and meta-analysis.
adult psychiatry
Journal
Evidence-based mental health
ISSN: 1468-960X
Titre abrégé: Evid Based Ment Health
Pays: England
ID NLM: 100883413
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
26
03
2019
revised:
14
04
2019
accepted:
29
04
2019
pubmed:
28
5
2019
medline:
21
7
2020
entrez:
26
5
2019
Statut:
ppublish
Résumé
Cost-effectiveness analyses that use quality-adjusted life-years (QALYs) allow comparing the value for money of interventions across different health problems. Health state utility values (HSUVs) are crucial to calculate QALYs. These are weights attached to a given health state reflecting preferences in health-related quality of life (HRQoL). In schizophrenia, there is extensive evidence about the consequences of this condition on HRQoL. Besides, several interventions have claimed to be cost-effective in terms of QALYs gained. Despite this evidence, a systematic review of HSUVs has not been conducted. Therefore, we aim to synthesise the evidence about HSUVs in schizophrenia. We will conduct a systematic review of the literature about HSUVs in people with schizophrenia following the Preferred Reporting Items for Systematic review and Meta-Analysis and the International Society for Pharmacoeconomics and Outcomes Research task force recommendations. The submissions records of eight electronic peer-reviewed databases and three health technology assessment (HTA) agencies will be searched. Quantitative synthesis will be carried out in comparable studies, using random-effects meta-analysis. Heterogeneity will be explored using meta-regression if more than 10 studies per covariate are found. A narrative synthesis and methodological quality of included studies will be also reported. This review will provide a synthesis of the HSUVs estimated for different states experienced by people with schizophrenia. This will inform analysts when calculating QALYs, using values in a more transparent and accountable manner. Finally, it will shed light on evidence gaps and limitations about this measure in mental health. CRD42019123582.
Identifiants
pubmed: 31126911
pii: ebmental-2019-300089
doi: 10.1136/ebmental-2019-300089
pmc: PMC10270392
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
142-144Informations de copyright
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Value Health. 2012 Jul-Aug;15(5):639-49
pubmed: 22867772
Pharmacoeconomics. 2015 Nov;33(11):1101-5
pubmed: 26133293
Value Health. 2016 Sep - Oct;19(6):704-719
pubmed: 27712695
Value Health. 2011 Jan;14(1):102-9
pubmed: 21211492
BMJ. 2014 Feb 12;348:g1173
pubmed: 24523363
Syst Rev. 2015 Feb 21;4:15
pubmed: 25875206
Value Health. 2013 Jun;16(4):686-95
pubmed: 23796303
Schizophr Bull. 2018 Oct 17;44(6):1195-1203
pubmed: 29762765
Neuropsychiatr Dis Treat. 2016 Feb 16;12:357-73
pubmed: 26937191
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
PLoS One. 2013;8(1):e55176
pubmed: 23372832
Expert Rev Pharmacoecon Outcomes Res. 2018 Jun;18(3):267-275
pubmed: 29347854
Int J Technol Assess Health Care. 2017 Jan;33(4):472-480
pubmed: 29065942
Qual Life Res. 2016 Apr;25(4):925-34
pubmed: 26385367
Lancet. 2018 Oct 27;392(10157):1553-1598
pubmed: 30314863
Schizophr Bull. 2010 Jan;36(1):94-103
pubmed: 19955388
Lancet Psychiatry. 2017 Apr;4(4):295-301
pubmed: 28237639
Evid Based Ment Health. 2014 May;17(2):53-7
pubmed: 24692250
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Pharmacoeconomics. 2018 Sep;36(9):1043-1061
pubmed: 29750430
Pharmacoeconomics. 2017 Jan;35(1):25-42
pubmed: 27557994
Value Health. 2019 Mar;22(3):267-275
pubmed: 30832964
Evid Based Ment Health. 2018 May;21(2):72-76
pubmed: 29650528
Pharmacoeconomics. 2010;28(12):1109-21
pubmed: 21080736
Pharmacoeconomics. 2017 Dec;35(Suppl 1):43-55
pubmed: 29052156